

Myocardial perfusion with an intravascular contrast agent

Submission date 03/04/2009	Recruitment status Stopped	☐ Prospectively registered ☐ Protocol
Registration date 13/11/2009	Overall study status Stopped	☐ Statistical analysis plan ☐ Results
Last Edited 14/06/2013	Condition category Circulatory System	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Eike Nagel

Contact details

The Rayne Institute - Division of Imaging Sciences
School of Medicine - King's College London
4th Floor, Lambeth Wing
St. Thomas Hospital
London
United Kingdom
SE1 7EH

Additional identifiers

Protocol serial number

25/11/2008 Final_v1.1

Study information

Scientific Title

Quantitative assessment of myocardial perfusion with magnetic resonance using an intravascular contrast agent: an open label trial

Study objectives

The primary objective of the trial will be to develop and evaluate new methods for the true quantitative measurement of blood supply to the heart using cardiac magnetic resonance (MR) and gadolinium-based MR contrast agents.

The secondary objectives of the trial will be:

1. To optimise the MR sequence parameters for the acquisition of MR first pass perfusion images
2. To determine the best dosage and scheme of administration for the intravascular MR contrast agent Vasovist®
3. To compare the results obtained with different types of contrast agents and different MR sequences
4. To validate the newly developed methods for quantitative measurement of myocardial perfusion against ¹³N-Ammonia positron emission tomography (PET) and with fractional flow reserve (FFR)
5. To test the reproducibility of the different MR approaches to quantitative myocardial perfusion assessment

Ethics approval required

Old ethics approval format

Ethics approval(s)

NHS National Research Ethics Service - Guy's Research Ethics Committee approved on the 29th February 2009 (ref: 08/H0804/95; Protocol v.1.1)

Primary study design

Interventional

Study design

Non-randomised non-controlled open label trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Coronary artery disease

Interventions

14/06/2013: Please note that this trial was stopped in April 2011.

First pass perfusion magnetic resonance during stress with intravenous (i.v.) adenosine.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Adenosine, Vasovist®

Primary outcome(s)

1. Comparison and validation of Vasovist® perfusion MR versus conventional perfusion MR, PET and FFR:
 - 1.1. Comparison between standard clinical qualitative evaluation of MR perfusion and fully quantitative evaluation
 - 1.2. Validation against 13N-Ammonia PET (research indication) and/or FFR (only performed following a clinical indication as part of routine clinical care)
2. Reproducibility of Vasovist® first pass MR perfusion: comparison of the results between different perfusion MR scans

Key secondary outcome(s)

1. MR sequence optimisation for Vasovist® perfusion:
 - 1.1. Signal to noise ratio in the images acquired with different MR techniques
 - 1.2. Prevalence of artefacts in the images
2. Vasovist® dose selection:
 - 2.1. Saturation effect of the peak contrast agent signal in the myocardium
 - 2.2. Signal to noise ratio
 - 2.3. Prevalence of artefacts in the images

Completion date

28/02/2010

Reason abandoned (if study stopped)

Participant recruitment issue

Eligibility

Key inclusion criteria

1. Known coronary artery disease (with or without prior percutaneous revascularisation)
2. Indication for percutaneous coronary intervention (PCI)
3. The subject is 18 years of age or older, either sex
4. The subject is conscious and able to comply with study procedures
5. Written informed consent has been obtained

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

1. Contraindications for magnetic resonance imaging (MRI)
2. Contraindications to gadolinium-based contrast agents (known allergies or a contra-indication to gadolinium (Gd) chelates or renal insufficiency)
3. Contraindications to adenosine stress:
 - 3.1. Myocardial infarction less than 3 days
 - 3.2. Unstable angina pectoris
 - 3.3. Severe arterial hypertension
 - 3.4. Asthma or severe obstructive pulmonary disease requiring treatment (chronic obstructive pulmonary disease [COPD])
 - 3.5. Sick sinus syndrome or a symptomatic bradycardia, atrioventricular (AV) block greater than IIa, trifascicular block
 - 3.6. Allergy against vasodilator
 - 3.7. Allergy against gadolinium-based contrast agents or renal insufficiency
 - 3.8. Other contraindications for adenosine or dipyridamole administration
4. The subject has significant cardiac arrhythmia (i.e. atrial fibrillation)
5. Pregnancy
6. Heart failure (New York Heart Association [NYHA] grade IV)
7. The subject's electrocardiogram (ECG) shows prolonged QT interval
8. Severe arterial hypotension (less than 90 mmHg systolic)
9. Claustrophobia

Date of first enrolment

15/04/2009

Date of final enrolment

28/02/2010

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

The Rayne Institute - Division of Imaging Sciences

London

United Kingdom

SE1 7EH

Sponsor information

Organisation

King's College London (UK)

ROR

<https://ror.org/0220mzb33>

Funder(s)

Funder type

Industry

Funder Name

Bayer Schering Pharma AG (Germany)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No